TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04115644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Group 2 (ketorolac): will receive an injection of 3 cc 0.25% Marcaine without epinephrine and 2 cc ketorolac 30 mg/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Marcaine (placebo)
Description: Group 1 (control): will receive an injection of 5 cc 0.25% Marcaine without epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marcaine (placebo)
Description: Group 1 (control): will receive an injection of 5 cc 0.25% Marcaine without epinephrine

Intervention type: DRUG
Group type: OTHER
Intervention: Marcaine (placebo)
Description: Group 1 (control): will receive an injection of 5 cc 0.25% Marcaine without epinephrine
Study: NCT03405753

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Aronia, washout and then placebo
Description: Three tablets three times à day for three months then washout for three months, then three placebo tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, washout and then aronia
Description: Three tablets three times à day for three months, then washout for three months, then three aronia tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, washout and then aronia
Description: Three tablets three times à day for three months, then washout for three months, then three aronia tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
Study: NCT02322931

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-operative C-arm CT imaging
Description: 1. Two intra-operative C-arm 3D reconstruction scans with the Ziehm Vision FD Vario 3D immediately after treatment implantation, once with the TRUS probe inserted and once with the TRUS probe removed. This involves approximately 10 fluoroscopy snapshots of the prostate.~2. Two TRUS Sagittal B-mode sweeps and two TRUS axial B-mode sweeps, once mid-way, i.e. after implanting a sub-set of the seeds, and once at the end of the implantation procedure.~3. One Cine loop C-arm scan in the sagittal plane while retracting the probe.~4. One 3D C-arm scan immediately after the treatment, with the TRUS probe removed and the patient in the supine position (i.e. legs down).
Study: NCT04115644

Intervention type: DRUG
Group type: OTHER
Intervention: Kenalog
Description: Group 3 (kenalog): 4 cc 0.25% Marcaine without epinephrine and 1 cc triamcinolone.
Study: NCT00236197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole sodium
Description: Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally,placebo once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
Study: NCT04131894

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autogenous dentin graft

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autogenous dentin graft

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich fibrin (PRF)
Study: NCT05151419

Intervention type: PROCEDURE
Group type: OTHER
Intervention: bronchoscpe
Description: bronchoscopic biopsy from lung mass using cryobiopsy and forceps
Study: NCT02577575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal Spray
Description: 40 IU of the saline nasal spray will be administered once at the beginning of the visit.
Study: NCT01407887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artesunate (AS) - amodiaquine (AQ) - methylene blue (MB)
Description: The group AS-AQ-MB will receive once daily a fixed dose AS-AQ formulation combined with once daily MB over a three days period.
Study: NCT02496156

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Clinical Practice
Description: Diabetes management and education related to insulin pump or continuous glucose monitor as currently practiced at the enrolling site.
Study: NCT03818997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Patient will receive Atezolizumab 840 mg IV every 2 weeks until PD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Patient will receive Atezolizumab 840 mg IV every 2 weeks until PD
Study: NCT03843112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vivag Plus
Description: Contains two lactobacilli strains; l. gasseri and l. rhamnosus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: Vaginal supplements
Study: NCT02349022

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [89Zr]Df-IAB2M
Study: NCT00967148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinzaparin
Description: The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
Study: NCT02343081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study: NCT00967148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Description: The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
Study: NCT04516187

Intervention type: DIAGNOSTIC_TEST
Intervention: signs and symptoms, blood tests
Description: signs and symptoms as observed by the treating physician + blood tests (CRP, Procalcitonin, White blood cell count)

Intervention type: DIAGNOSTIC_TEST
Intervention: signs and symptoms, blood tests
Description: signs and symptoms as observed by the treating physician + blood tests (CRP, Procalcitonin, White blood cell count)
Study: NCT02496156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Medical Decision Making
Description: Access to and use of multimedia decision aid websites to facilitate adolescent and parent decision making about incorporating these devices into the diabetes management regimen.
Study: NCT02500407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTCT4465A (Mosunetuzumab) IV
Description: Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTCT4465A (Mosunetuzumab) IV
Description: Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants assigned to an atezolizumab combination group will receive atezolizumab 1200 mg administered as an IV infusion in combination with BTCT4465A (Mosunetuzumab).
Study: NCT01229202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: single bevacizumab subtenon injection of 1.25 mg. at end of trabeculectomy surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: single bevacizumab subtenon injection of 1.25 mg. at end of trabeculectomy surgery
Study: NCT02500407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants assigned to an atezolizumab combination group will receive atezolizumab 1200 mg administered as an IV infusion in combination with BTCT4465A (Mosunetuzumab).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTCT4465A (Mosunetuzumab) SC
Description: Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTCT4465A (Mosunetuzumab) SC
Description: Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via SC injection.
Study: NCT03530306

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS1-PS4
Description: Participants in this arm shall be given PS1 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS6-PS10
Description: Participants in this arm shall be given PS6 during the first half of treatment and PS10 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS7-PS4
Description: Participants in this arm shall be given PS7 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS9-PS6
Description: Participants in this arm shall be given PS9 during the first half of treatment and PS6 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
Study: NCT01003964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP
Description: Irinotecan (65 mg/m2) IV on day1 , 8 Cisplatin (30 mg/m2) IV on day 1 , 8 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP
Description: Gemcitabine (1250 mg/m2) IV on D 1, 8. Cisplatin (75 mg/m2) IV on D1 every 3 weeks.
Study: NCT03682146

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prostatectomy
Description: Comparison of robotic-assisted and conventional laparoscopic radical prostatectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prostatectomy
Description: Comparison of robotic-assisted and conventional laparoscopic radical prostatectomy
Study: NCT04199689

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9vHPV Vaccine
Description: 9-valent human papillomavirus vaccine (9vHPV) is an aluminum-adjuvanted recombinant protein vaccine prepared from the highly purified virus-like particles (VLPs) of the recombinant major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 given as a 0.5 mL intramuscular injection.
Study: NCT03524092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab SC
Description: Administered SC

Intervention type: DRUG
Group type: OTHER
Intervention: Mirikizumab SC
Description: Administered SC

Intervention type: DRUG
Group type: OTHER
Intervention: Mirikizumab IV
Description: Administered IV

Intervention type: DRUG
Group type: OTHER
Intervention: Mirikizumab IV
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Administered SC

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo SC
Description: Administered SC
Study: NCT03381274

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive oleclumab in combination with osimertinib or AZD4635 as stated in the arms' description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive oleclumab in combination with osimertinib or AZD4635 as stated in the arms' description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive oleclumab in combination with osimertinib or AZD4635 as stated in the arms' description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive oleclumab in combination with osimertinib or AZD4635 as stated in the arms' description.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive oleclumab in combination with osimertinib or AZD4635 as stated in the arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Participants will receive osimertinib in combination with oleclumab as stated in the arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Participants will receive osimertinib in combination with oleclumab as stated in the arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635
Description: Participants will receive AZD4635 in combination with oleclumab as stated in the arms' description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635
Description: Participants will receive AZD4635 in combination with oleclumab as stated in the arms' description.
Study: NCT04199689

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline for Injection)
Description: 0.9% sodium chloride given as a 0.5-mL intramuscular injection
Study: NCT00713401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Esmolol low dose infusion according to manufacturer's instructions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Esmolol low dose infusion according to manufacturer's instructions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Esmolol low dose infusion according to manufacturer's instructions
Study: NCT03381274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635
Description: Participants will receive AZD4635 in combination with oleclumab as stated in the arms' description.
Study: NCT03315182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV9.CMV.hNAGLU
Description: Adeno-associated virus serotype 9 carrying the human NAGLU gene under the control of a CMV enhancer/promoter (rAAV9.CMV.hNAGLU) will be delivered one-time through a venous catheter inserted into a peripheral limb vein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV9.CMV.hNAGLU
Description: Adeno-associated virus serotype 9 carrying the human NAGLU gene under the control of a CMV enhancer/promoter (rAAV9.CMV.hNAGLU) will be delivered one-time through a venous catheter inserted into a peripheral limb vein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV9.CMV.hNAGLU
Description: Adeno-associated virus serotype 9 carrying the human NAGLU gene under the control of a CMV enhancer/promoter (rAAV9.CMV.hNAGLU) will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
Study: NCT02794740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X0002
Description: External Spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X0002
Description: External Spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X0002
Description: External Spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X0002
Description: External Spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: External Spray
Study: NCT04699305

Intervention type: DEVICE
Intervention: ActiGraft
Description: Whole blood clot (WBC) gel
Study: NCT02794740

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: External Spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: External Spray
Study: NCT00330798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nepafenac 0.1%
Description: Nepafenac 0.1% randomly assigned to one eye, with ketorolac 0.4% in the fellow eye for contralateral post-surgical use.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ketorolac 0.4%
Description: Keterolac 0.4% randomly assigned to one eye, with nepafenac 0.1% in the fellow eye for contralateral post-surgical use.
Study: NCT02646488

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow Up Post Intervention 27 Months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow Up Post Intervention 27 Months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow Up Post Intervention 30 Months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow Up Post Intervention 30 Months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow Up Post Intervention 33 Months
Study: NCT03494933

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CRT-P implantation
Description: Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive on top a CRT-P device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRT-D implantation
Description: Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive on top a CRT-D device.
Study: NCT04414046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haploidentical Hematopoietic Cell Transplantation
Description: TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
Study: NCT00005967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Study: NCT02600676

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electric Nerve Stimulation (TENS) - active
Description: TENS is a non-invasive method using surface electrodes. Except a few cases with local skin irritation in the area where the electrodes are applied, there is no evidence of side effects of TENS treatment.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous Electric Nerve Stimulation (TENS) - placebo
Study: NCT04136067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0268-0965
Description: One daily dose of 1.5, 4.0 or 6.0 nmol/kg administered s.c. (subcutaneously, under the skin) for 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: One daily dose of 3.0 nmol/kg administered s.c. for 6 days
Study: NCT01732328

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium plus vitamin D
Study: NCT02331628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESWT - Extracorporeal Shockwave Therapy
Description: Patients will receive:~* Four applications of EWST to be delivered to the affected hip and /or knee over a period of eight weeks : starting week 8\\52 from baseline until and including week 14\\52, one dose every two weeks ± 3 days), administered by the principal investigator.~* Dosage will be calculated for each participant, by the manufacturer, according to the size of NHO as recorded on X-ray.~* The energy flux density (EFD) will be 'high level'~* All participants will be supplied with headphones to reduce the noise level emitted by the machine.
Study: NCT00113919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Dexamethasone 40 mg PO 1-4 Thalidomide 200 mg PO 1-6 Cisplatin\* 10 mg/m, Continuous infusion 1-4 Adriamycin\*\* 10 mg/m2, Continuous infusion 1-4 Cyclophosphamide 400 mg/2, Continuous infusion 1-4 Etoposide 40 mg/m2, Continuous infusion 1-4 All doses will be based on calculated body weight (actual weight + ideal body weight ÷ 2) and height, and not to exceed a BSA of 2.0 m2 The daily dose of cyclophosphamide, etoposide, and cisplatin will be mixed in a 1L bag of NS to be UAMS infused over 24 hours. Adriamycin will be mixed in at least 50cc D5W to be infused over 24 hours
Study: NCT02697708

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Potassium control diet
Description: No additional potassium.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Potassium gluconate diet
Description: 1000 mg K from potassium gluconate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potato Diet
Description: 1000 mg K from potatoes.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: French Fries Diet
Description: 1000 mg K from French Fries.
Study: NCT02789839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Blood test of 30mL

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medullar test
Description: Medullar test for 2-5mL and a smear
Study: NCT00420095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human insulin 30/70
Description: Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro low mix
Description: Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
Study: NCT03006315

Intervention type: DEVICE
Intervention: Garmin Vivofit device
Description: Participants will be bio-monitored using the Garmin Vivofit mobile wearable device at baseline (at least 1-7 days prior to treatment initiation) and during induction chemotherapy up to completion of 6 cycles. For those patients continuing with ASCT, patients will be bio-monitored up to 90 days post ASCT.

Intervention type: DEVICE
Intervention: Garmin Vivofit device
Description: Participants will be bio-monitored using the Garmin Vivofit mobile wearable device at baseline (at least 1-7 days prior to treatment initiation) and during induction chemotherapy up to completion of 6 cycles. For those patients continuing with ASCT, patients will be bio-monitored up to 90 days post ASCT.

Intervention type: BEHAVIORAL
Intervention: Mobile Health quality of life assessements

Intervention type: BEHAVIORAL
Intervention: Mobile Health quality of life assessements
Study: NCT03810495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone implant
Description: 1.8 g implant containing 60% naltrexone
Study: NCT00713401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Esmolol low dose infusion according to manufacturer's instructions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Esmolol low dose infusion according to manufacturer's instructions
Study: NCT04157660

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen application
Description: Oxygen application Supplemental oxygen via mask

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham room air
Description: Room air will be applied via mask
Study: NCT03818997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patient will receive Paclitaxel 80 mg/m2 IV on day 1, 8 and 15 of a 28 day cycle until PD